The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Several studies have shown through chemical inhibitors that p38 mitogen-activated protein kinase (MAPK) promotes vascular smooth muscle cell (VSMC) differentiation. Here, we evaluate the effects of knocking down a dominant p38MAPK isoform on VSMC differentiation. Methods and Results-Knockdown of p38MAPKα (MAPK14) in human coronary artery SMCs unexpectedly increases VSMC differentiation genes, such as miR145, ACTA2, CNN1, LMOD1, and TAGLN, with little change in the expression of serum response factor (SRF) and 2 SRF cofactors, myocardin (MYOCD) and myocardin-related transcription factor A (MKL1). A variety of chemical and biological inhibitors demonstrate a critical role for a RhoA-MKL1-SRF-dependent pathway in mediating these effects. MAPK14 knockdown promotes MKL1 nuclear localization and VSMC marker expression, an effect partially reversed with Y27632; in contrast, MAP2K6 (MKK6) blocks MKL1 nuclear import and VSMC marker expression. Immunostaining and Western blotting of injured mouse carotid arteries reveal elevated MAPK14 (both total and phosphorylated) and reduced VSMC marker expression. Conclusion-Reduced MAPK14 expression evokes unanticipated increases in VSMC contractile genes, suggesting an unrecognized negative regulatory role for MAPK14 signaling in VSMC differentiation. (Arterioscler Thromb Vasc Biol. 2013;33:378-386.) Key Words: differentiation ◼ myocardin ◼ p38 mitogen-activated protein kinase ◼ smooth muscle
V ascular smooth muscle cell (VSMC) differentiation is characterized by the expression of a growing number of cell-restricted genes encoding ion channels, cytocontractile and matrix proteins, and noncoding RNAs, which together establish a structural and functional phenotype conducive for the maintenance of vascular homeostasis. 1, 2 Unlike skeletal and cardiac muscle cells, which are largely terminally differentiated, VSMCs exhibit phenotypic adaptation under a variety of experimental and clinical conditions and, as a consequence, lose their normal differentiated state and may partially convert to several distinct cell types. [3] [4] [5] [6] Such changes in the normal VSMC differentiated state are thought to underlie several human vascular diseases, including atherosclerosis, Alzheimer angiopathy, hypertension, restenosis, and transplant arteriopathy. 1, [7] [8] [9] Thus, there has been much work devoted to elucidate the molecular underpinnings of normal VSMC differentiation and how this program is redirected under pathological conditions. A growing number of transcriptional mediators have been shown to promote VSMC differentiation, including retinoidactivated nuclear receptors, 10 c-MYB, 11 ZEB, 12 SMAD3, 13 PITX2, 14 NRF3, 15 and activated Notch receptors. 16 However, the dominant transcription factor essential for VSMC differentiation is the widely expressed serum response factor (SRF), 17 which binds >1200 variations of a 10-bp cis element known as a CArG box located in the promoter/intronic region of the majority of VSMC-restricted genes. 18 SRF directs cell-and contextdependent programs of gene expression through its association with over 60 cofactors. For example, myocardin (MYOCD) is a cardiac and VSMC-enriched SRF cofactor 19 that powerfully activates CArG-dependent [19] [20] [21] [22] and CArG-independent 13, 23 target genes. MYOCD is necessary 24, 25 and sufficient 26 for VSMC differentiation and contractile function, although there is some genetic evidence to suggest that a subpopulation of VSMCs can differentiate in the absence of MYOCD. 27 Importantly, expression levels of Myocd mRNA are reduced under conditions of phenotypic adaptation. 20, 28, 29 Given the critical importance of MYOCD for VSMC phenotype, there has been much focus on the signaling pathways governing transcriptional and posttranscriptional control of MYOCD activity or expression.
Two widely expressed paralogs of MYOCD have been identified: myocardin-related transcription factors A and B (MKL1/MKL2). 30 Unlike MYOCD, which is constitutively localized to the nucleus, MKL1/2 possess several N-terminal Arg-Pro-Glu-Leu (RPEL) domains for binding to monomeric globular actin, thus sequestering these SRF cofactors in the cytosol. 31 Upon actin polymerization, MKL1/2 are released from depleted globular actin and translocate into the nucleus where they associate with SRF to stimulate CArG-dependent target gene expression. 32, 33 This dynamic nucleocytoplasmic shuttling mechanism underscores a connection between actin cytoskeletal dynamics and nuclear changes in gene expression. 33 Central to this mechanism of MKL1/2 shuttling is the activation of the small GTPase, RhoA. 32 In VSMCs, RhoAdependent actin polymerization 34 coupled to MKL1 nuclear localization 35 facilitates VSMC contractile gene expression. Several extracellular stimuli have been demonstrated to stimulate RhoA-MKL1, leading to VSMC-restricted gene expression including transforming growth factor-β1 (TGFβ1)/ BMP4 36 and sphinghosine-1-phosphate. 37, 38 However, a full understanding of all signaling cascades that converge upon RhoA-MKL1 to initiate VSMC-restricted gene expression is incomplete.
Numerous reports document TGFβ1 and downstream signaling pathways in the activation of VSMC-restricted gene expression. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] p38 mitogen-activated protein kinase (p38MAPK) is among the signaling pathways shown to be pivotal for TGFβ1-induced VSMC differentiation. 44, 46, 49, 51 p38MAPK comprises 4 different isoforms encoded in 4 distinct gene loci. Among these isoforms, p38MAPKα (MAPK14) and p38MAPKβ (MAPK11) have received most attention in terms of expression and activity, based on their high sensitivity to the selective inhibitors, SB203580 and SB202190. 52 Although there has been general consensus as to the inhibitory action of these SB compounds or dominantnegative mutants of p38MAPK on TGFβ1-directed VSMC differentiation, whether altered expression of MAPK14 per se has any effect on this program is unknown. Here, we report the unanticipated finding of an enhanced VSMC differentiated phenotype with knockdown of MAPK14 and an opposing downregulation of such VSMC contractile markers upon constitutive activation of MAPK14 with its upstream kinase, MKK6. Mechanistic studies support a role for the RhoA/ ROCK-MKL1-SRF axis in mediating VSMC gene transcription with reduced p38MAPK. These results suggest a heretofore unrecognized role for p38MAPK in the negative control of the VSMC differentiation program.
Materials and Methods
An expanded Methods section is available in the online-only Data Supplement.
Cell Culture
Human coronary artery SMCs (HCASMCs), primary mouse aortic SMCs, human pulmonary artery SMCs, rat aortic SMCs, 10T1/2 cells, human lung fibroblasts, and Hek293 cells were used as indicated throughout.
siRNA Transfections
Growing cells were seeded in 6-well plates and cultured until 70% confluent and then transfected with the expression plasmids, scramble small interfering RNA (siRNA) controls, or siRNAs to MAPK14, SRF, MYOCD, or MKL1.
Immunofluorescence Microscopy
Both conventional immunofluorescence and confocal microscopy were performed to analyze expression of VSMC markers, actin cytoskeleton, and MKL1 nucleocytoplasmic shuttling.
Adenoviral-Mediated Gene Transfer
HCASMCs were transduced with the indicated adenoviral constructs at varying multiplicity of infection. Negative control cells were transduced with the same adenoviral backbone carrying the bacterial LacZ gene.
Luciferase Assay
10T1/2 cells were seeded in 24-well plates and grown to subconfluence, whereupon transfections were carried out with various expression plasmids and reporter genes, and luciferase assay was performed in standard fashion.
Mouse Carotid Artery Ligation
Twelve-week-old C57BL/6J mice were subjected to complete or partial common carotid artery ligation as described. 53, 54 Immunohistochemistry Sections of carotid artery were prepared and quenched with 3% H 2 O 2 and then subjected to antigen retrieval before applying primary antibody.
Results

Knockdown of Endogenous MAPK14 Induces the VSMC Contractile Phenotype
We recently reported that a commonly used p38MAPK inhibitor, SB203580, completely blocked TGFβ1-induced miR143/145 and other VSMC contractile genes. 51 Each of the 4 p38MAPK isoforms is detectable in cultured HCASMCs as demonstrated by conventional and quantitative reverse transcriptase-polymerase chain reaction ( Figure I in the online-only Data Supplement). Because the α isoform (MAPK14) is of higher expression than the other SB203580sensitive isoform (MAPK11) and more is known about MAPK14 in VSMCs, we sought to design siRNA to MAPK14 to confirm whether its expression, per se, is important for TGFβ1-induced VSMC differentiation. Upon MAPK14 knockdown, miR145 levels increase after TGFβ1 stimulation ( Figure I in the online-only Data Supplement). These results prompted us to examine whether VSMC contractile genes are similarly elevated upon knockdown of MAPK14. Indeed, CArG-dependent CNN1, ACTA2, LMOD1, 55 and TAGLN increase with MAPK14 depletion in HCASMCs ( Figure 1A ). Such VSMC gene induction is specific because levels of KLF5 and PDCD4 mRNA show little or no change ( Figure 1A ). Furthermore, other more widely expressed CArG-containing genes (eg, SRF, VCL, and EGR1) exhibit minor alterations in expression with MAPK14 knockdown ( Figure 1A and data not shown). We also note that reduced MAPK14 increases both baseline and TGFβ1-induced ACTA2 and CNN1 protein expression ( Figure 1B ). Comparable increases are seen with 3 independent siRNAs to MAPK14 ( Figure II in the online-only Data Supplement). Primary mouse aortic SMCs treated with siRNA to Mapk14 also display strong induction of VSMC contractile markers at both the mRNA and protein levels ( Figure 1C and D). We observe similar results in rat aortic SMCs as well as PAC1 and A7r5 VSMCs (data not shown), suggesting that the effects of Mapk14 knockdown on the VSMC contractile gene program are broadly applicable across different species. Importantly, we find little change in Myocd or Mkl1 transcripts ( Figure 1C ) and no induction of MKL1 protein (below) with Mapk14 depletion, implying that the induction of VSMC contractile genes is independent of any increase in these powerful upstream SRF coactivators. Because mRNA and protein levels of MAPK14 are high in cultured VSMCs ( Figure I in the online-only Data Supplement; Figure  1 and data below), gain-of-function studies are not practical. However, increasing amounts of MAPK14 have an inhibitory effect on Tagln (Sm22α) promoter activity in 10T1/2 cells ( Figure III in the online-only Data Supplement). Taken together, these results provide strong evidence to support a novel and widely evident activation of the VSMC contractile program upon knockdown of MAPK14.
Knockdown of Endogenous MAPK14 Increases Filamentous Actin in VSMCs
An important characteristic of differentiated VSMCs is the existence of an array of myofilaments reflecting the polymerization of globular actin into filamentous actin (F-actin). We therefore analyzed the intracellular composition of F-actin by staining HCASMCs with phalloidin in the absence or presence of siRNA to MAPK14. Results show an increase in F-actin upon MAPK14 knockdown ( Figure IV in the onlineonly Data Supplement). Consistent with Western blotting data ( Figure 1B) , there is an attending elevation in CNN1 staining in HCASMCs treated with siRNA to MAPK14 ( Figure IV in the online-only Data Supplement). Similar results are seen in human pulmonary artery SMCs (data not shown). These data demonstrate that depletion of endogenous MAPK14 is sufficient to promote the formation of F-actin assembly in human VSMC.
Heterologous MAPK14 Rescues Synergistic Activation of ACTA2 With Combined MKL1 and MAPK14 Knockdown
MKL1 can potently stimulate SRF-dependent VSMC contractile gene expression. 56 We asked whether MAPK14 knockdown can synergize with MKL1 to potentiate ACTA2 expression in Hek293 cells. Indeed, we observe clear synergy with combined MAPK14 knockdown and ectopic MKL1 expression ( Figure IID and IIE in the online-only Data Supplement). Importantly, this synergy is lost when we introduce an expression plasmid carrying mouse MAPK14 that is not targeted for knockdown with the siRNA to human MAPK14 ( Figure IIF in the online-only Data Supplement). Collectively, these data indicate that MAPK14 knockdown is not a result of an offtarget effect and that MKL1 may be an important mediator for siMAPK14-induced VSMC gene expression (see below).
siMAPK14-Mediated VSMC Gene Induction Is RhoA/SRF-Dependent
RhoA signaling plays a critical role in mediating VSMC gene expression through F-actin assembly, MKL1 nuclear translocation, and interaction with SRF. 34, 35 To test whether RhoA signaling underlies the increase in VSMC contractile proteins with MAPK14 knockdown, we used the Rhoassociated protein kinase (ROCK) inhibitor, Y27632. Results show that Y27632 attenuates the induction of CNN1 and TAGLN after MAPK14 knockdown ( Figure 2A ); expression of a dominant-negative RhoA also abolishes the increase in VSMC marker expression with siMAPK14 ( Figure 2B ). The RhoA inhibitor, CCG-1423, 57 blocks siMAPK14induced VSMC contractile proteins in both HCASMCs ( Figure 2C ) and pulmonary artery SMCs ( Figure V in the online-only Data Supplement). Furthermore, we observe a consistent increase in phosphorylated cofilin (CFL1), a downstream target of activated RhoA, 33 with MAPK14 knockdown ( Figure 2D ). Latrunculin B, a compound that blocks MKL1 nuclear shuttling through depolymerization of F-actin, 33 displays similar inhibitory effects on VSMC contractile protein activation with reduced MAPK14 ( Figure  2E ). Finally, siRNA knockdown of SRF nearly abolishes siMAPK14-induced stimulation of VSMC contractile proteins ( Figure 2F ). Taken together, these data suggest a RhoA-actin polymerization-SRF-dependent mechanism for the increase in VSMC contractile phenotype with MAPK14 knockdown.
siMAPK14-Mediated VSMC Gene Induction Requires MKL1, But Not MYOCD
We next sought to ascertain the relative contribution of MYOCD versus MKL1 in the activation of the VSMC contractile program with MAPK14 knockdown. We first examined the effects of siMAPK14 in human lung fibroblast cells because these cells express abundant MKL1 mRNA ( Figure  3A ) and protein (data not shown) with apparent low-level expression of MYOCD mRNA ( Figure 3A ). siMAPK14 treatment of human lung fibroblasts induces protein expression of CNN1 and ACTA2 ( Figure 3B ). Although knockdown of MYOCD in HCASMC results in an expected decrease in VSMC contractile markers, induction of such markers with MAPK14 knockdown persists even with reduced MYOCD (Figure 3C and D) . In contrast, MKL1 knockdown abrogates siMAPK14-induced VSMC contractile proteins in HCASMCs ( Figure 3E ). Similar results are found in human lung fibroblast cells (data not shown). These findings suggest that MKL1, rather than MYOCD, is the principal cofactor for siMAPK14-induced VSMC contractile marker expression. Human coronary artery SMCs (HCASMCs) treated with siMAPK14 overnight were serum-starved for 8 h and then treated for an additional 24 h with 2 ng/mL transforming growth factor-β1 (TGFβ1) in the absence or presence of Y27632 (10 μmol/L) before Western blotting (A). Growing HCASMCs transduced with adenovirus carrying dominantnegative RhoA (DNRhoA) or Lacz control overnight were treated with siMAPK14 for 8 h, and cells were serum-starved for another 48 h before Western analysis (B). HCASMCs transfected with siMAPK14 for 8 h were refed basal medium±CCG-1423 (3.3 μmol/L) overnight before stimulation with TGFβ1 (2 ng/mL) for 24 h (C). HCASMCs were transfected with siMAPK14 for 48 h and then stimulated with TGFβ1 (2 ng/mL) for another 24 h, whereupon Western blotting was done for the indicated proteins (D). HCASMCs were treated with siMAPK14 overnight and refed with differentiation medium for 6 h before adding latrunculin B (50 nmol/L) for 24 h and Western blotting of VSMC marker genes (E). HCASMCs transfected with the indicated siRNA overnight and maintained in growth medium for 48 h before Western blotting analysis (F). All data are representative of at least 3 independent experiments using different isolates of HCASMCs. MAPK14 indicates mitogen-activated protein kinase 14.
Reduced MAPK14 Promotes Nuclear Translocation of MKL1 in a ROCK-Dependent Manner
exhibits nucleocytoplasmic shuttling, 32, 33 we asked whether reduced MAPK14 has any influence on the cellular distribution of MKL1. We initially treated HCASMCs with siRNA to MAPK14 and then transduced cells with an adenovirus carrying HA-MKL1 to examine its cellular distribution profile (repeated attempts to interrogate endogenous MKL1 shuttling were not successful). Most ectopic MKL1 staining is confined to the cytosol of serum-starved HCASMCs with normal levels of MAPK14. However, MKL1 redistributes to the nuclear compartment upon siMAPK14 knockdown ( Figure 4A ). Quantitative analysis reveals that >80% of control cells display MKL1 in the cytosol, with a nearly equivalent percentage of cells residing in the nucleus upon MAPK14 knockdown ( Figure  4B ). Importantly, the effects of MAPK14 knockdown could be partially reversed upon cotreatment with the ROCK inhibitor, Y27632 ( Figure 4A and 4B) . Collectively, these observations suggest that depletion of endogenous MAPK14 enables MKL1 to translocate into the nucleus in a Rho-dependent manner, thereby effecting SRF-dependent VSMC contractile gene expression.
Sustained Activation of MAPK14 Reduces VSMC Markers and MKL1 Nuclear Localization
Previous work has shown that a transient increase in MAPK14 activity mediates TGFβ1-induced VSMC contractile phenotype, an effect blocked by SB203580. 44, 49, 51 MKK6 is an upstream, dual-specificity kinase that selectively phosphorylates MAPK14. 52 Overexpressing constitutively active MKK6 in HCASMCs results in a dose-dependent increase in phospho-MAPK14 ( Figure 5A ). Importantly, similarly treated cells show a concurrent decrease in the expression of VSMC markers ( Figure 5A ; Figure VIA in the onlineonly Data Supplement). The MKK6-mediated decrease in VSMC markers seems to be specific for phosphor-MAPK14 because simultaneous knockdown of MAPK14 abolishes Representative results from 3 independent experiments are shown (C). HCASMC were transduced with adenovirus carrying HA-MKL1±MKK6 for 24 h and then refed fresh growth medium for an additional 24 h to promote nuclear importation of MKL1. Cells were then visualized by confocal immunofluorescence microscopy, and quantitative analysis of MKL1 cellular localization was carried out (D, E). such repression ( Figure 5B ). MKK6 abrogates basal Tagln promoter activity in the presence of ectopic MAPK14, but such inhibition is rescued upon coexpression of a dominantnegative (kinase-deficient) MAPK14 ( Figure 5C ). In contrast to the elevation in MKL1 nuclear localization with MAPK14 knockdown (Figure 4 ), ectopic MKK6 expression completely suppresses serum-induced MKL1 nuclear localization ( Figure  5D and 5E). Furthermore, both SB203580 ( Figure VIB 
Reciprocal Expression of MYH11 and MAPK14 in Neointima After Arterial Injury
To determine relative expression of MAPK14 versus VSMC markers in vivo, we turned to a well-defined model of neointimal formation. In the uninjured vessel wall, there is abundant expression of MYH11, the gold standard marker for VSMC lineages. 58 Upon ligation injury, levels of MYH11 are lower in the neointima versus underlying medial tissue. However, MAPK14 expression is notably elevated in the neointima versus media ( Figure 6A) . Similar changes are observed on Western blot analysis ( Figure 6B ). Importantly, most neointimal cells exhibit clear phosphorylated MAPK14 expression ( Figure 6A, panel e ), a finding consistent with Western blotting studies ( Figure 6B ).
Discussion
We previously reported that SB203580, a widely used inhibitor of p38MAPK, blocks TGFβ1-induced miR143/145 and other VSMC contractile genes, 51 which is consistent with the results reported by other groups. 44, 46, 49 These studies suggest that under conditions of TGFβ1 stimulation, p38MAPK signaling is important for VSMC differentiation through its stimulation of SRF/myocardin expression 51,59-61 (Figure 7) . The current study predicted that knockdown of p38MAPK would replicate results obtained with SB203580. However, we found the opposite result; knockdown of the dominant p38MAPK isoform (MAPK14) evokes a consistent elevation in VSMC contractile markers. Mechanistic studies support the involvement of a RhoA-MKL1-SRF axis in the activation of VSMC contractile genes upon knockdown of MAPK14. Consistent with these findings, we observe that overexpression of a constitutively active upstream kinase for p38MAPK, MKK6, inhibits VSMC differentiation, and this inhibitory effect is reversed upon treatment with either SB203580 or a kinase-deficient MAPK14. Importantly, injury to the vessel wall is associated with p38MAPK expression and activity in the evolving neointima concomitant with reduction in VSMC differentiation. Thus, we surmise that p38MAPK has opposing effects on VSMC differentiation depending on the nature of the stimulus: some factors (TGFβ1) promote VSMC differentiation, whereas stress conditions such as proliferative signals (below) or vascular trauma initiate negative regulation of VSMC differentiation (Figure 7 ). Evidence provided here supports the specificity of MAPK14 knockdown in the elevation of VSMC-restricted genes/proteins. First, we show that several independent siMAPK14 oligonucleotides mediate similar increases in VSMC contractile markers. Second, the synergy between siMAPK14 and MKL1 to potentiate VSMC contractile protein expression can be rescued upon addition of exogenous mouse MAPK14. Third, we find that siMAPK14-induced VSMC contractile gene expression is not limited to VSMC cultures; myofibroblasts are also similarly sensitive to siMAPK14, indicating that the negative regulatory role of MAPK14 on certain VSMC differentiation markers is a general phenomenon and not cell contextdependent. Fourth, only VSMC contractile genes are induced with siMAPK14; expression of other genes, such as KLF5, SRF, MKL1, and MYOCD, are not altered with siMAPK14. Because most of the VSMC contractile genes have ≥1 SRFbinding CArG boxes, 18 siMAPK14 knockdown likely occurs in an SRF-CArG-dependent fashion. Indeed, reducing SRF expression with siRNA or blocking its activity with CCG-1423 completely abolishes siMAPK14-induced VSMC gene expression.
There are several possibilities to explain why knockdown of MAPK14 stimulates rather than inhibits VSMC differentiation as one might expect from previous SB203580 compound studies. 44, 46, 49, 51, 62 First, the effects of p38MAPK rely largely on biological context, particularly the intensity and duration of kinase activity. 52 Second, although SB203580 is relatively specific for blocking p38MAPK, it has been reported to target other signaling pathways, such as cyclin G-associated kinase and SMAD 63, 64 ; thus, we cannot exclude an off-target effect of SB203580 on VSMC differentiation, particularly at higher concentrations (eg, 10 μmol/L). In this context, we have found that both SB203580 and BIRB (another p38MAPK inhibitor) augment levels of VSMC marker expression at low concentrations, whereas inhibition is seen at higher concentrations ( Figure VII in the online-only Data Supplement). We suggest that investigators exercise caution when using these inhibitors of p38MAPK. Finally, because there are reported kinase-independent functions of p38MAPK, 52 we cannot rule out a role for p38MAPK in some other capacity, such as scaffolding a critical negative mediator of VSMC differentiation. Distinguishing between the relative contribution of p38MAPK kinase activity or some other functional characteristic will require detailed genetic studies including knock-in experiments.
p38MAPK has been shown to have varied effects on VSMC phenotype. For example, certain growth factors such as platelet-derived growth factor 65 or endothelin-1 66 stimulate p38MAPK and subsequent VSMC proliferation. Furthermore, VSMC-specific expression of a dominant-negative p38MAPK results in reduced platelet-derived growth factor-induced VSMC proliferation and a diminution in neointimal formation. 67 These studies point to an important role for the p38MAPK pathway in mediating VSMC proliferative responses. However, there is a growing literature to suggest that an SB203580-sensitive pathway of VSMC differentiation exists. 44, 46, 49, 51, 62 Until now, however, no studies have formally tested whether reducing p38MAPK expression phenocopies the inhibition of VSMC differentiation via SB203580. Here, we have clearly demonstrated the unexpected augmentation of VSMC differentiation marker expression upon knockdown of MAPK14 and further demonstrate that constitutively active MKK6 overexpression decreases VSMC genes. A previous study revealed that siRNA knockdown of p38MAPK blocked platelet-derived growth factor-induced VSMC proliferation, although there was no investigation into VSMC marker expression 67 ; however, MKK6 has been demonstrated to suppress VSMC markers. 62 Importantly, we show that the MKK6-mediated suppression of VSMC markers can be partially rescued with either a dominant-negative MAPK14 or SB203580, suggesting that the inhibition of VSMC markers is, at least in part, dependent on the kinase activity of MAPK14. It will be of interest to define the downstream substrates of MAPK14 that are mediating the suppressive effects on VSMC phenotype. Computational prediction of Ser-Thr phosphorylation sites using NetPhos 2.0 (http://www. cbs.dtu.dk/services/NetPhos/) reveals RhoA, G-actin, SRF, and MKL1 as potential substrates for MAPK14. Studies are underway to define substrates of MAPK14 that explain the negative regulatory role of this signaling protein in VSMC contractile gene expression, as well as the in vivo function of MAPK14 through VSMC-specific Mapk14 knockout mice.
There is increasing appreciation for an active role of the actin cytoskeleton in mediating transcriptional programs of gene expression. 33 Here, we provide several findings that support a role for actin dynamics involving RhoA-SRF-MKL1 in the control of VSMC differentiation gene expression through MAPK14 knockdown. First, Y27632 (a ROCK inhibitor) and a dominant-negative RhoA decrease siMAPK14-induced VSMC contractile gene expression. Second, CCG-1423, a small-molecule inhibitor of RhoA transcriptional signaling 57 and latrunculin B, an inhibitor of actin polymerization, attenuate the effect of siMAPK14 treatment on VSMC marker expression. Third, knockdown of SRF abolishes the activation of VSMC differentiation markers upon siMAPK14 knockdown. Finally, siMAPK14 knockdown enhances F-actin assembly and MKL1 nuclear localization, an effect partially reversed with Y27632 treatment, and activation of VSMC markers is attenuated upon concurrent knockdown of MKL1. It will be informative to investigate how MAPK14 affects the RhoA-MKL1-SRF axis to attenuate VSMC marker expression in, for example, a disease setting, such as acute vascular occlusion.
In summary, we found a heretofore unrecognized role for p38MAPK (MAPK14) in the negative regulation of VSMC differentiation. The fact that higher levels of MAPK14 and phospho-MAPK14 are observed in the neointima where less VSMC contractile protein expression exists suggests that p38MAPK may be an important therapeutic target for combating vascular diseases.
